---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-195895"
form_type: "8-K"
ticker: "AVIR"
cik: "0001593899"
company_name: "Atea Pharmaceuticals, Inc."
filed_at: "2024-08-07T23:59:59+00:00"
generated_at: "2026-05-31T11:46:10.987575+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Atea reports Q2 net loss $40.5M; Phase 2 HCV data show 97% SVR12; Phase 3 COVID-19 trial due 2H24

## Summary
- Net loss of $40.5M for Q2 2024 (diluted EPS -$0.48) vs $28.2M loss in Q2 2023; cash balance $502.2M.
- R&D expenses rose to $34.7M (+$12.6M YoY) driven by Phase 2/3 trial costs.
- Full enrollment in global Phase 2 HCV study (bemnifosbuvir + ruzasvir); SVR12 results expected 4Q 2024.
- Lead-in cohort (n=60) at EASL achieved 97% SVR12 with 8-week treatment; no drug-related serious AEs.
- Phase 3 SUNRISE-3 (bemnifosbuvir for COVID-19) topline data anticipated in 2H 2024.

## SEC filing metadata
- accession: 0001193125-24-195895
- form_type: 8-K
- ticker: AVIR
- cik: 0001593899
- company_name: Atea Pharmaceuticals, Inc.
- filed_at: 2024-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1593899/000119312524195895/0001193125-24-195895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1593899/000119312524195895/d880974d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-195895
- JSON: https://secwatch.observer/filing/0001193125-24-195895.json
- Plain text: https://secwatch.observer/filing/0001193125-24-195895.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.